Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Nuvalent, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CAMBRIDGE, MASS. , AUG. 13, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON CREATINGPRECISELYTARGETED THERAPIES FOR CLINICALLY PROVEN KINASE TARGETS IN CANCER, TODAY ANNOUNCED THAT PIVOTAL DATA FOR ZIDESAMTINIB, A NOVEL ROS1-SELECTIVE INHIBITOR, IN TKI (TYROSINE KINASE INHIBITOR) PRE-TREATED PATIENTS WITH ADVANCED ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) FROM THE GLOBAL ARROS-1 PHASE 1/2 CLINICAL TRIAL, IN ADDITION TO PRELIMINARY DATA FOR TKI-NAVE PATIENTS, WILL BE PRESENTED AS PART OF THE PRESIDENTIAL SYMPOSIUM AT THE IASLC 2025 WORLD CONFERENCE ON LUNG CANCER (WCLC 2025).

NUVALENT TO PRESENT PIVOTAL DATA FROM ARROS-1 CLINICAL TRIAL OF ZIDESAMTINIB FOR TKI PRE-TREATED PATIENTS WITH ADVANCED ROS1-POSITIVE NSCLC AT WCLC 2025 PRESIDENTIAL SYMPOSIUM

INITIATED ROLLING NDA SUBMISSION FOR ZIDESAMTINIB FOR TKI PRE-TREATED PATIENTS WITH ADVANCED ROS1-POSITIVE NSCLC, WITH TARGET COMPLETION IN THE THIRD QUARTER OF 2025 INITIATED ALKAZAR PHASE 3 RANDOMIZED, CONTROLLED TRIAL OF NELADALKIB FOR FRONT-LINE ALK-POSITIVE NSCLC TOPLINE PIVOTAL DATA FOR NELADALKIB FOR TKI PRE-TREATED PATIENTS WITH ADVANCED ALK-POSITIVE NSCLC EXPECTED BY YEAR-END 2025 PRELIMINARY DATA FOR NELADALKIB IN PATIENTS WITH ALK-POSITIVE SOLID TUMORS BEYOND NSCLC TO BE PRESENTED AT THE ESMO CONGRESS 2025 JASON WATERS, MBA, PROMOTED TO SENIOR VICE PRESIDENT, COMMERCIAL CAMBRIDGE, MASS. , AUG. 7, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON CREATINGPRECISELYTARGETED THERAPIES FOR CLINICALLY PROVEN KINASE TARGETS IN CANCER, TODAY OUTLINED PIPELINE AND BUSINESS ACHIEVEMENTS, REITERATED KEY ANTICIPATED MILESTONES, AND REPORTED SECOND QUARTER 2025 FINANCIAL RESULTS.

NUVALENT HIGHLIGHTS PIPELINE AND BUSINESS ACHIEVEMENTS, REITERATES KEY ANTICIPATED MILESTONES, AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

CAMBRIDGE, MASS. , JULY 21, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON CREATINGPRECISELYTARGETED THERAPIES FOR CLINICALLY PROVEN KINASE TARGETS IN CANCER, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN ALKAZAR, THE COMPANY'S GLOBAL PHASE 3 RANDOMIZED, CONTROLLED TRIAL EVALUATING NELADALKIB FOR TKI-NAVE PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), VERSUS ALECENSA (ALECTINIB),A FRONT-LINE STANDARD OF CARE.

NUVALENT ANNOUNCES INITIATION OF ALKAZAR PHASE 3 RANDOMIZED, CONTROLLED TRIAL EVALUATING NELADALKIB FOR PATIENTS WITH TKI-NAVE ALK-POSITIVE NSCLC

ALIGNED WITH FDA ONNDA SUBMISSION STRATEGY FOR TKI PRE-TREATED PATIENTS WITH ADVANCED ROS1-POSITIVE NSCLC AND PARTICIPATION IN REAL-TIME ONCOLOGY REVIEW; THE COMPANY PLANS TO INITIATE A ROLLING NDA SUBMISSION IN JULY 2025 WITH TARGET COMPLETION IN THE THIRD QUARTER OF 2025 IN 117 ROS1 TKI PRE-TREATED PATIENTS, INCLUDING 50% WHO HAD RECEIVED  2 PRIOR ROS1 TKIS  CHEMOTHERAPY, ORR BY BICR WAS 44% (95% CI: 34, 53) WITH INITIAL ESTIMATED DURABILITY OF RESPONSE OF 78% AT THE 12-MONTH LANDMARK AND 62% AT THE 18-MONTH LANDMARK IN THE SUBSET OF 55 PATIENTS TREATED WITH 1 PRIOR ROS1 TKI (CRIZOTINIB OR ENTRECTINIB)  CHEMOTHERAPY, ORR WAS 51% (95% CI: 37, 65) WITH INITIAL ESTIMATED DURABILITY OF RESPONSE OF 93% AT THE 12- AND 18-MONTH LANDMARKS ZIDESAMTINIB DEMONSTRATED INTRACRANIAL RESPONSES, ACTIVITY AGAINST TUMORS WITH A ROS1 G2032R RESISTANCE MUTATION, AND A GENERALLY WELL-TOLERATED SAFETY PROFILE, INCLUDING LOW RATES OF DOSE REDUCTION (10%) AND DISCONTINUATION (2%), CONSISTENT WITH ITS ROS1-SELECTIVE, TRK-SPARING DESIGN COMPANY ANNOUNCES PROGRESS IN THE FRONT-LINE DEVELOPMENT STRATEGIES FOR ITS PARALLEL LEAD PROGRAMS IN ROS1-POSITIVE AND ALK-POSITIVE NSCLC COMPANY TO HOST A CONFERENCE CALL TODAY, JUNE 24TH AT 8:00AM ET CAMBRIDGE, MASS. , JUNE 24, 2025 /PRNEWSWIRE/ --NUVALENT, INC.(NASDAQ: NUVL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON CREATINGPRECISELYTARGETED THERAPIES FOR CLINICALLY PROVEN KINASE TARGETS IN CANCER, TODAY ANNOUNCED POSITIVE PIVOTAL DATA FOR ZIDESAMTINIB, A NOVEL ROS1-SELECTIVE INHIBITOR, IN TKI (TYROSINE KINASE INHIBITOR) PRE-TREATED PATIENTS WITH ADVANCED ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) FROM THE GLOBAL ARROS-1 PHASE 1/2 CLINICAL TRIAL.

NUVALENT ANNOUNCES POSITIVE PIVOTAL DATA FROM ARROS-1 CLINICAL TRIAL OF ZIDESAMTINIB FOR TKI PRE-TREATED PATIENTS WITH ADVANCED ROS1-POSITIVE NSCLC

COMPANY TO HOST WEBCAST AND CONFERENCE CALL ON JUNE 24, 2025 AT 8:00AM ET CAMBRIDGE, MASS. , JUNE 23, 2025 /PRNEWSWIRE/ -- NUVALENT, INC.(NASDAQ: NUVL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON CREATINGPRECISELYTARGETED THERAPIES FOR CLINICALLY PROVEN KINASE TARGETS IN CANCER, TODAY ANNOUNCED THAT THE COMPANY WILL HOST A WEBCAST AND CONFERENCE CALL ON TUESDAY, JUNE 24, 2025 AT 8:00 A.M.

NUVALENT ANNOUNCES TIMING OF PIVOTAL DATA FOR TKI PRE-TREATED PATIENTS WITH ADVANCED ROS1-POSITIVE NSCLC FROM ARROS-1 CLINICAL TRIAL OF ZIDESAMTINIB

CAMBRIDGE, MASS. , JUNE 18, 2025 /PRNEWSWIRE/ --NUVALENT, INC.(NASDAQ: NUVL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON CREATINGPRECISELYTARGETED THERAPIES FOR CLINICALLY PROVEN KINASE TARGETS IN CANCER, TODAY ANNOUNCED THE APPOINTMENT OF CHRISTY OLIGER TO ITS BOARD OF DIRECTORS.

NUVALENT APPOINTS CHRISTY OLIGER TO BOARD OF DIRECTORS

TOPLINE PIVOTAL DATA EXPECTED FOR ZIDESAMTINIB IN TKI PRE-TREATED ROS1-POSITIVE NSCLC POPULATION IN THE FIRST HALF OF 2025 IN SUPPORT OF ANTICIPATED FIRST NDA SUBMISSION BY MID-YEAR 2025 INITIATION OF ALKAZAR PHASE 3 RANDOMIZED, CONTROLLED TRIAL OF NELADALKIB FOR FRONT-LINE ALK-POSITIVE NSCLC PLANNED FOR FIRST HALF OF 2025 PIVOTAL DATA FOR NELADALKIB IN TKI PRE-TREATED ALK-POSITIVE NSCLC POPULATION ANTICIPATED BY YEAR-END 2025 STRENGTHENED LEADERSHIP TEAM WITH KEY INTERNAL PROMOTIONS CAMBRIDGE, MASS. , MAY 8, 2025 /PRNEWSWIRE/ --NUVALENT, INC.(NASDAQ: NUVL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON CREATINGPRECISELYTARGETED THERAPIES FOR CLINICALLY PROVEN KINASE TARGETS IN CANCER, TODAY OUTLINED PIPELINE AND BUSINESS PROGRESS, REITERATED KEY ANTICIPATED MILESTONES, AND REPORTED FIRST QUARTER 2025 FINANCIAL RESULTS.

NUVALENT OUTLINES RECENT PIPELINE AND BUSINESS PROGRESS, REITERATES KEY ANTICIPATED MILESTONES, AND REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

CAMBRIDGE, MASS. , APRIL 29, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON CREATINGPRECISELYTARGETED THERAPIES FOR CLINICALLY PROVEN KINASE TARGETS IN CANCER, TODAY ANNOUNCED THE PUBLICATION OF A MANUSCRIPT IN MOLECULAR CANCER THERAPEUTICS, A JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH,WHICH SUPPORTS THE RATIONAL MOLECULAR DESIGN OF ZIDESAMTINIB, ITS NOVEL AND SELECTIVE ROS1 INHIBITOR.

NUVALENT ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS REINFORCING RATIONAL MOLECULAR DESIGN OF ZIDESAMTINIB AS A NOVEL ROS1-SELECTIVE INHIBITOR

CAMBRIDGE, MASS. , APRIL 23, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON CREATINGPRECISELYTARGETED THERAPIES FOR CLINICALLY PROVEN KINASE TARGETS IN CANCER, TODAY ANNOUNCED TWO "TRIAL IN PROGRESS" POSTER PRESENTATIONS FOR ITS NOVEL ALK-SELECTIVE INHIBITOR, NELADALKIB, AND NOVEL HER2-SELECTIVE INHIBITOR, NVL-330, AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING FROM MAY 30  JUNE 5, 2025, IN CHICAGO.

NUVALENT TO PRESENT TRIAL IN PROGRESS POSTERS FOR THE ALKAZAR TRIAL OF NELADALKIB AND HEROEX-1 TRIAL OF NVL-330 AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

CAMBRIDGE, MASS. , APRIL 1, 2025 /PRNEWSWIRE/ -- NUVALENT, INC. (NASDAQ: NUVL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON CREATINGPRECISELYTARGETED THERAPIES FOR CLINICALLY PROVEN KINASE TARGETS IN CANCER, TODAY ANNOUNCED THAT JAMES PORTER, PH.D.

Nuvalent, Inc.

NUVL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Nuvalent, Inc.

NUVL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NUVL